Clovis Oncology Announces First Patient Treated With Hydrobromide Salt Tablet Formulation of CO-1686 in Its Ongoing Phase I/II Clinical Study
Published: Aug 29, 2013
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology (NASDAQ:CLVS) announced today that it has dosed the first patient with its new hydrobromide salt tablet formulation of CO-1686 in its ongoing Phase I dose-finding portion of its Phase I/II clinical study. CO-1686 is the Company’s novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating mutations as well as the dominant resistance mutation T790M.
Help employers find you! Check out all the jobs and post your resume.